Physician profile
Jonathan I Ury
NPI 1467945964
$490.69
in general payments reported to CMS, 2019-2025
14 companies · $38.91 in 2025
The $38.91 reported for 2025 was less than what a typical General Practice (Dentist) provider received nationally (typical 2025 total: $74.60).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.66 · 2020: $13.51 · 2021: $79.22 · 2022: $219 · 2023: $38.39 · 2024: $74.83 · 2025: $38.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $152.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulpdent Corporation | $152.40 | 2022-2023 | |
| Janssen Biotech, INC. | $81.19 | 2019-2022 | |
| Viiv Healthcare Company | $55.55 | 2024 | Dovato, Rukobia |
| 3m Company | $31.01 | 2022 | |
| Abbvie INC. | $24.60 | 2021 | |
| Merck Sharp & Dohme LLC | $23.62 | 2025 | Capvaxive, Pifeltro |
| Patterson Companies, INC. | $23.35 | 2022 | |
| Seqirus USA INC | $19.28 | 2024 | Flucelvax, Fluad |
| Coltene Whaledent INC. | $15.85 | 2022 | |
| Theratechnologies INC. | $15.44 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.29 | 2025 | Caplyta |
| Kerr Corporation | $14.15 | 2022 | |
| Emd Serono, INC. | $13.51 | 2020 | |
| Kettenbach LP | $5.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Ury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.